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Objective: To evaluate the impact of pharmacist-led warfarin management and
standardized treatment protocol.
Methods: A retrospective cohort study was carried out in a cardiology referral hospital
located in central Kuala Lumpur, Malaysia, from 2009 to 2014. The inclusion criteria
were: adult patients who were diagnosed and treated for atrial fibrillation (AF) with
warfarin, attended the warfarin medication therapy adherence clinic (WMTAC) for at
least 12 weeks, and with at least four international normalized ratio (INR) readings.
The electronic medical records were reviewed for demographics, type of AF, warfarin
dose, INRs, adverse events, co-morbidities, and drug–drug interactions. The outcome
measures included the mean time to therapeutic INR, the mean percentage of time in
therapeutic range (TTR), bleeding events, and common drug interactions.
Results: Out of 473 patients, 151 patients fulfilled the inclusion criteria. The findings
revealed that there were significant associations between the usual medical care (UMC)
group and pharmacist-led WMTAC in terms of TTR (p = 0.01) and INR (p = 0.02)
levels. A positive impact of pharmacists’ involvement in the WMTAC clinic was where
the “pharmacist’s recommendation accepted” (p = 0.01) and “expanded therapeutic
INR range” (p = 0.04) were statistically significantly higher in the WMTAC group.
Conclusion: There was a significant positive association between the pharmacist-
led WMTAC and anticoagulation effect (therapeutic TTR, INR). The identified findings
revealed that expanded role of pharmacist in pharmacist-managed warfarin therapy is
beneficial to optimize the warfarin therapy. This study also highlighted the critical roles
that pharmacists can actively play to ensure optimal anticoagulation pharmaceutical
care.
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Key messages:
What is already known on this subject?
• Pharmacist-managed warfarin therapy is beneficial for optimizing warfarin therapy.
In such therapy, recommendations such as dose adjustment and safer alternative
drugs (given drug–drug interactions and/or food–drug interactions) are made.
• The active involvement of pharmacists in warfarin adherence clinics could
significantly improve adherence.
• However, the warfarin treatment outcomes from UMC, pharmacist-and-physician-
led care and pharmacist-led care have not been studied.
• The impact of the implementation of the standardized protocol for the warfarin
adherence clinic has not been assessed.
What this study adds?
• INR levels among UMC group and WMTAC group were significantly different.
• Though the TTR level for the WMTAC group was not significantly different than the
UMC group, it was higher and close to the targeted 60% level.
• The identified findings show that pharmacists’ focus on intervention for missed
doses, adherence and dose adjustment provide positive impact on patients’
warfarin therapy.
Keywords: warfarin, anticoagulant, international normalized ratio, percent time in therapeutic INR range,
multidisciplinary care
INTRODUCTION
Atrial fibrillation (AF) constitutes a significant public health
problem and is considered the most common arrhythmia of
clinical significance (Zubaid et al., 2013). Due to the growing
prevalence and incidence of AF across the world, recent
epidemiological statistics confirm the emergence of this disorder
as a global epidemic (Ministry of Health Malaysia, 2012). In
2010, it was estimated that about 33.5 million individuals, or
0.5% of the world’s population, has AF (Zubaid et al., 2013).
This rise in the epidemiology of AF is expected to continue
with the aging of societies worldwide (La Brooy and Ho,
2015).
Although frequently associated with palpitations and
fluttering, AF remains asymptomatic for many patients. One
of the main risk factors of AF is hypertension, and a study by
Wong et al. (2013) reported that 0.75% of hypertensive patients
have asymptomatic AF (AAF). The risk is similar among both
genders. Asymptomatic patients with comorbid hypertension
aged 61 and above were associated with a 10.6 times higher
probability of AAF. Wong et al. (2013) estimated that there were
49,029 Malaysians with AAF in 2010. Hence, greater emphasis on
diagnostic ascertainment, screening, and prevention strategies
are important to reduce the risk of AAF-related complications
(Wong et al., 2013).
Asian populations were reported to have lower incidence and
prevalence of AF than Western populations. The estimate is
0.4–1% of the general Asian population. However, the relative
risks of AF-associated stroke and mortality in Asian and
Western populations are similar (Ministry of Health Malaysia,
2012; La Brooy and Ho, 2015). According to guidelines for
management of AF in United States and Europe, non-valvular
AF patients with additional risk factors for ischemic stroke and
systemic thromboembolism should be prescribed with chronic
oral anticoagulants, of which warfarin remains the gold standard.
Both local and international literature have pointed out the lack
of proper standard treatment guidelines and recommendations
regarding how to manage patients taking warfarin. The treatment
is often complicated when patients are on dual antiplatelet
therapy. Patients discharged from hospital with concomitant
aspirin, clopidogrel, and warfarin are subjected to greater risk
of bleeding events. Furthermore, patients’ outcomes can be
affected by interactions of warfarin with food or traditional and
complementary medicines.
To the best of our knowledge, only one study so far has been
conducted in Malaysia to evaluate pharmacists’ management of
warfarin treatment, but this particular study did not evaluate
the impact of the warfarin medication therapy adherence clinic
(WMTAC) protocol, which was implemented in January 2013
(Thanimalai et al., 2013).
The main aim of the study was to compare the international
normalized ratio (INR) and percentage of time in therapeutic
range (TTR) levels among a group of AF patients who received
warfarin under usual medical care (UMC) before the Malaysian
warfarin protocol was implemented, and among group of AF
patients who received warfarin under the WMTAC after the
implementation of the protocol. This study also aimed to
determine the therapeutic outcomes (for example, the number
of bleeding events) and interventions conducted by the WMTAC
pharmacists.
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MATERIALS AND METHODS
Study Setting
This study was a retrospective observational study conducted at a
public hospital located in Kuala Lumpur, Malaysia.
Study Design
This was a retrospective cohort study using pre- versus post-
WMTAC protocol design. AF patients who followed up in the
warfarin clinics between 2009 and 2014 were considered and their
medical records were retrieved. The flow chart for recruitment of
patients is shown in Figure 1.
This study consisted of two groups:
(1) Group 1 (pre-protocol group): patients were recruited
from January 2009 until December 2012. This group
consisted of patients who were initiated on warfarin
under standard medical team management known as UMC
before the WMTAC protocol was introduced. The warfarin
clinic was mainly led by physicians and a referral to a
pharmacist was only made when necessary.
(2) Group 2 (post-protocol group): patients were recruited
from January 2013 until December 2014, after
implementation of the new Ministry of Health (MOH)
WMTAC protocol. This group was managed by both
pharmacists and physicians and called the WMTAC
group. In this group, pharmacists were more involved, and
have expanded role in patient education and counseling.
They were also allowed to implement the protocol and
recommend any dosage adjustment and/or continuation
of warfarin therapy.
Ethics Statement
The study protocol was approved by the Clinical Research
Centre of the patients’ recruitment hospital and the Medical
Research & Ethics Committee at the Malaysian Ministry of
Health. All data collection and information was kept confidential
according to the ethical requirements. All aspects of the study
protocol, including access to and use of the patient clinical
information was authorized by the medical ethics committee
and the local health authorities before initiation of the study.
Prior approval to conduct this study was obtained from: Medical
Research and Ethics Committee, UiTM; National Institutes
of Health (NIH), Ministry of Health; and Medical Research
and Ethics Committee (MREC), Ministry of Health. The
NMRR registration number for this study is NMRR-14-1623-
20026 (IIR).
Study Population
Recruitment of Participants
All patients taking warfarin were screened initially from the
hospital medical record department and the warfarin patient
record book from the warfarin medical clinic. All new AF
patients receiving warfarin treatment from January 2009 until
December 2014 were identified and potential patients for this
study were recruited using the Electronic Medical Record (EMR)
system and the warfarin patient record book (Figure 1). The
warfarin patient record book contained information such as the
patient’s name, registration number, INR readings, and remarks
for each patient. Patients were identified after being rechecked in
the EMR.
Inclusion and Exclusion Criteria
All new patients who were admitted to the recruitment hospital
and received warfarin during the defined study period were
considered. The inclusion criteria for recruitment of patients into
the study were:
(1) Adult patients (≥18 years old) who were diagnosed and
treated for AF plus required warfarin therapy and attended
the WMTAC clinic at the recruitment hospital.
(2) All patients diagnosed with AF and followed up regularly
for at least 12 weeks with the WMTAC clinic.
(3) Stable patients on warfarin with at least four INR readings
and a steady state for at least 12 weeks.
The exclusion criteria for recruitment of patients into the study
were:
(1) Patients who were diagnosed with AF but had not been
prescribed with warfarin.
(2) Patients who defaulted treatment or were unable to comply
with the follow-up requirements.
(3) Patients who discontinued or deferred from warfarin
therapy or who were discharged to another hospital at any
point.
(4) Patients for whom important medical and medication data
was missing.
Data Collection
A pre-validated data collection form was used to extract
clinical information on the study population from inpatient
records, chart reviews, and outpatient physician office records.
The information gathered was then evaluated to identify the
pharmaceutical care issues following Pharmaceutical Issues
Classification by Krska et al. (2002). The appropriateness of each
patient’s pharmacological treatment was assessed according to
local and international guidelines.
The overall percentage TTR was calculated using the
method described by Rosendaal et al. (1993), which uses linear
interpolation to estimate the time spent at each INR value. INR
desk 4.0 Software was used to calculate the TTR percentage.
An expanded INR was set between ranges of 1.8 and 3.2. The
expanded INR is defined as therapeutic range INR±0.2, and such
variation of INR from therapeutic range is considered clinically
insignificant, hence no dosage adjustment is required (Saokaew
et al., 2012). This is in accordance with MOH WMTAC protocol
(Ministry of Health Malaysia, 2010). All INR values were entered
into the software and analyzed automatically for every patient.
TTR readings were calculated as percentages.
Data and Statistical Analysis
Descriptive statistics were used to describe demographic
characteristics of the patients, social habits, comorbidities,
CHA2DS2VASc and HASBLED scores, as well as the number
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FIGURE 1 | Sampling of patients.
of bleeding events. Percentages and frequencies were used
for the categorical variables, while means and standard
deviations were calculated for the continuous variables. Mann–
Whitney test was used to determine the differences between
interventions (expanded therapeutic INR range, missed doses,
and accepted pharmacist recommendation) and INR level
before and after starting the protocol. All analyses were
performed using SPSS statistical software version 20 (SPSS Inc.,
Chicago, IL, United States). The significance level was set at
p-value < 0.05.
Study Outcomes
Primary Outcomes
The primary outcomes were the control of INR for at least 12
weeks after starting warfarin treatment and the percentage of
TTR in patients in the WMTAC group compared to the UMC
group.
Secondary Outcomes
The secondary outcome measurements included complications
or adverse events (including minor bleeding symptoms) among
the AF patients. Major bleeding was defined as an overt
clinical bleed, or documented intracranial or retroperitoneal
hemorrhage. Minor bleeding events included bruising, nose
bleeds, gum bleeding, hematuria, and rectal bleeding not
requiring further action. INR readings and bleeding symptoms
were monitored closely at the WMTAC. A stroke was defined
as an ischemic cerebral infarction caused by an embolic or
thrombotic occlusion of a major intracranial artery. Examples of
possible warfarin adverse events are thromboembolic and major
hemorrhagic complications.
Furthermore, interventions during consultation, including
pharmacists’ recommendation of dosage adjustment, expanded
therapeutic INR range, and detection of missed dose, were
recorded and compared for pre- and post-protocol groups.
RESULTS
Characteristics of Patients
This study identified 473 AF patients who were receiving warfarin
therapy. Out of the 473 patients, 62.25% (n = 322) patients were
found ineligible as they did not fulfill the study inclusion criteria.
Patients in UMC group were selected from eligible AF
patients from January 2009 until December 2012. The records
of patients in WMTAC group were selected from January 2013
until December 2014. This WMTAC group consisted of new AF
patients selected in the mentioned year, plus patients from the
same cohort with UMC group who were still receiving warfarin
therapy. In this study, 126 patients were recruited for UMC
group, and 106 patients documented under WMTAC group. As
some of the patients in WMTAC were continued from UMC
group, the total number of patients involved were 151 subjects.
The details of the socio-demographic characteristics and
common comorbidities of the patients are shown in Table 1.
Detailed Risk Score: CHA2DS2VASc and HASBLED scores
of the patients are shown in Table 2 (note: the higher the
HASBLED scores, the higher the bleeding tendency among the
warfarin patients). CHA2DS2VASc and HASBLED remain as
well-accepted predictive tools on risk of undesired events among
warfarin patients (Lip et al., 2013).
INR and TTR Levels before and after
Starting Protocol
Differences in INR and TTR levels between pre- and
post-protocol groups were tested using Mann–Whitney
Frontiers in Pharmacology | www.frontiersin.org 4 November 2017 | Volume 8 | Article 637
fphar-08-00637 November 8, 2017 Time: 18:2 # 5
Aidit et al. Monitoring of Anticoagulation Therapy
TABLE 1 | Demographic data, social habits, and comorbidities.
Demographic data and social
habits
n (%)
Gender Female 80 (53.0)
Male 71 (47.0)
Race Chinese 86 (57.0)
Malay 59 (39.1)
Indian 6 (4.0)
Age 30–39 3 (2.0)
[Median = 66, mean = 66.11 ± SD
10.81]
40–49 5 (3.3)
[Range 34–89] 50–59 33 (21.9)
60–69 50 (33.1)
70–79 43 (28.5)
80–89 17 (11.3)
Smoker No 132 (87.4)
Yes 19 (12.6)
Alcoholic No 141 (93.4)
Yes 10 (6.6)
Comorbidities Hypertension 120 (79.5)
Diabetes mellitus 58 (38.4)
Stroke 29 (19.2)
Hyperlipidemia 24 (15.9)
Congestive heart failure 23 (15.2)
Ischemic heart disease 20 (13.2)
Chronic kidney disease∗ 10 (6.6)
Hyperthyroidism 7 (4.6)
Gout 3 (2.0)
Valvular heart disease 3 (2.0)
∗Only one case for end-stage renal failure was found.
TABLE 2 | Risk scoring of included patients.
Risk score Score n (%)
CHA2DS2VASc
[Median = 3, mean 0.11 ± SD 1.40] 0 8 (5.3)
[Range 0–6] 1 28 (18.5)
2 37 (24.5)
3 40 (26.5)
4 26 (17.2)
5 7 (4.6)
6 5 (3.3)
HASBLED score
[Median = 1, mean = 1.25 ± SD 0.93] 0 35 (23.2)
[Range 0–4] 1 59 (39.1)
2 43 (28.5)
3 13 (8.6)
4 1 (0.7)
test. The TTR level was higher in WMTAC group, but
was not statistically significant (Table 3). To facilitate
comparison between interventional groups, these patients’
results in terms of TTR were divided into five groups
(Table 4).
TABLE 3 | International normalized ratio (INR) and time in therapeutic range (TTR)
in UMC and WMTAC.
UMC WMTAC p-value
(n = 126) (n = 106)
INR level, mean ± SD 2.09 ± 0.31 2.18 ± 0.30 0.04∗
TTR level, mean ± SD 59.25 ± 20.74 63.97 ± 19.41 0.12
∗p-value is significant < 0.05.
TABLE 4 | Time in therapeutic range (TTR).
TTR reading (%) UMC WMTAC
(n = 126, %) (n = 106, %)
Range 1–100
1–20 17 (11.2) 15 (9.9)
21–40 33 (21.9) 39 (19.2)
41–60 51 (33.8) 42 (27.9)
61–80 53 (35.1) 64 (42.3)
81–100 33 (21.9) 59 (39.1)
TABLE 5 | Effect of UMC versus WMTAC on anticoagulation control.
Interventions UMC WMTAC
(n = 126, %) (n = 106, %)
Accepted pharmacist
recommendation
Yes 119 (94.4) 106 (100.0)
No 7 (5.6) 0 (0.0)
Expanded therapeutic INR
range
Yes 98 (77.8) 96 (90.6)
No 28 (22.2) 10 (9.4)
Missed doses Yes 0 (0.0) 1 (0.9)
No 126 (100.0) 105 (99.1)
Pharmacist’s Recommendation
Accepted, Expanded Therapeutic INR
Range and Missed Doses Events
Results revealed that the pharmacists’ involvement in the
WMTAC clinic had a positive impact, as more pharmacist
recommendations were accepted in the WMTAC than UMC
group (p= 0.01; Table 5).
DISCUSSION
Bleeding Complication
Most of the patients did not experience bleeding symptoms either
before or after the implementation of the protocol (Table 6).
This may be due to interventions and proper counseling during
counseling sessions with patients. All symptoms such as bleeding
or thrombotic symptoms were included in the counseling part
and charted in the progress notes of the patients. A study
conducted by Rossiter et al. (2013) stated that patients on
warfarin treatment can be associated with hemorrhagic side-
effects. For example, they may be prone to gastrointestinal
bleeding and hemorrhagic strokes (Rosendaal et al., 1993).
A study by Poon et al. (2007) illustrated that minor bleeding
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events were more frequent among the pharmacist-monitored
group with 50 patients against 17 patients in UMC, with
p < 0.01. This study adopted a standardized electronic template
that specifically listed each minor bleeding symptom, where
the pharmacists reviewed and documented symptoms with the
patients during each anticoagulation service encounter (Poon
et al., 2007). The findings from the current study were consistent
with the findings of the study by Poon et al. (2007) as more
bleeding events were detected during the sessions with the
WMTAC group.
A study by Jennings et al. (2008) from 2004 to 2006 showed
that a pharmacist’s involvement in anticoagulation management
can lead to a reduction in thromboses (4.6 to 3.9%), major bleeds
(8.7 to 3.3%), and minor bleeds (4.6 to 3.5%). Hence, pharmacists
do have important roles in managing warfarin therapy according
to the protocol.
INR and TTR Readings in UMC and
WMTAC Group
INR levels were analyzed in these two groups: UMC and
WMTAC. A similar comparison was done by Saokaew et al.
(2013), who reported a significant improvement in INR level
from the UMC to the WMTAC group. When compared to UMC
group, implementation of pharmacist-managed warfarin therapy
(PMWT) significantly improved patients’ anticoagulation control
(Saokaew et al., 2013). Similar findings were found in a study
by Chamberlain et al. (2001) where the anticoagulation clinic
group had better anticoagulation control than the traditional care
group. Comparing INR values outside the target range produced
significantly more variation within the traditional care group
(Chamberlain et al., 2001).
A study by Poon et al. (2007) indicated that pharmacist-
monitored anticoagulation therapy significantly reduced
thromboembolic events among older patients compared to the
traditionally monitored groups. The study also reported that
more patients in the traditional physician-monitored group
had sub-therapeutic INR measurement ≤1.5 and they did not
return as quickly for dosage adjustment (Poon et al., 2007). In
addition, a prospective study by Padron and Miyares (2013)
carried out in the Jackson Memorial Hospital, Miami, reported
that involvement of pharmacists in anticoagulation management
can enhance standards of care and ensure the protocols were
upheld, therefore improving patients’ outcomes.
Results from a cross-sectional study by Hasan et al. (2011)
found that MTAC patients showed better INR control (p= 0.006)
than patients from the physician clinic. The study also showed a
positive correlation between patients’ knowledge and education
level (p = 0.001; Hasan et al., 2011). While physicians in
cardiology clinics were responsible for both AF patients and
patients with other cardiovascular issues, MTAC pharmacists
concentrated on warfarin patients only. The study asserted that
such focus of pharmacists helped to improve patients’ INR
control (Hasan et al., 2011).
In current study, although INR level of WMTAC group is
significantly higher than UMC group (Table 3), the reported
values were both within targeted INR range. However, patients’
education level was not evaluated in current study. There was also
no assessment of the adherence of patients, as this study was a
retrospective study.
In this study, the TTR levels were compared between these two
groups: UMC and WMTAC. The results show an improvement
in TTR group 61–80 increasing from 35.1 (n = 53) to 42.3%
(n = 64). In addition, TTR group 81–100 also showed a positive
improvement as the TTR level improved from 21.9 (n = 33)
to 39.1% (n = 59). This result indicates positive impact of
pharmacist-managed WMTAC clinic (see Table 5).
Connolly et al. (2008) reported that a minimum TTR of
60% is vital to achieve treatment benefit of warfarin. Patients
who failed to achieve such target were documented to have
significantly greater risk of myocardial infarction, stroke and
systemic embolism event (White et al., 2007). Hence, the findings
of current study show the benefits of pharmacists’ interventions
in warfarin therapy.
Young et al. (2011) stated that both models of care (UMC and
pharmacist-led) may provide high-quality warfarin management,
resulting in TTR of over 60% in both groups. Nonetheless, the
results indicated that the patients from pharmacist care group
have significantly greater TTR (73%) than UMC group (65%).
The study also documented higher expanded TTR in pharmacist-
led group (p< 0.0001). The warfarin therapy from this study was
managed by delivering optimization of anticoagulation therapy
using an evidence-based protocol developed by pharmacists
(Young et al., 2011).
Meanwhile, studies done previously (Rosendaal et al., 1993;
Witt et al., 2005; Young et al., 2011) have suggested that
coordinated care and systemic approach in anticoagulation
management lead to improved outcomes and reduced adverse
events. Point-of-care INR clinic by pharmacists has also been
reported to increase TTR significantly among warfarin patients
(Rossiter et al., 2013).
According to a study undertaken in the Singapore General
Hospital by Kong et al. (2012), there was a superior enhancement
in the serial percentage of TTR (from 44.78 to 54.44%
with p < 0.05) when pharmacist-led care was introduced.
Overall findings showed that a low number of thrombotic and
bleeding events were detected. However, no statistical significant
differences were found during the study periods. In this study,
the delivery of anticoagulation care in the clinics necessitate the
services of well-trained pharmacists in order to ensure a greater
consistency, as pharmacists undertake a more substantial amount
of the workload. This study also documented a correlation
between increased number of experienced pharmacists and
patients’ TTR level (Kong et al., 2012). However, due to
retrospective nature of current study, the number and skill of
WMTAC pharmacists could not be determined.
Pharmacist’s Recommendation
Accepted, Expanded Therapeutic INR
Range, and Missed Doses Events
Interventions
The results show that expanded therapeutic INR range was
statistically significant with a p-value of 0.04. According to the
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TABLE 6 | Reported bleeding events of included patients.
Types of bleeding UMC n (%) WMTAC n (%)
Number of events bruises No bleeding event 143 (94.7) No bleeding event 125 (82.8)
One event 4 (2.6) One event 20 (13.2)
Two events 4 (2.6) Two events 5 (3.3)
Three events 0 (0.0) Three events 0 (0.0)
Four events 0 (0.0) Four events 1 (0.7)
Gum bleeding No bleeding event 146 (96.7) No bleeding event 139 (92.1)
One event 4 (2.6) One event 8 (5.3)
Two events 0 (0.0) Two events 4 (2.6)
Three events 1 (0.7) Three events 0 (0.0)
Blood in saliva No bleeding event 150 (99.3) No bleeding event 149 (98.7)
One event 0 (0.0) One event 1 (0.7)
Two events 1 (0.7) Two events 1 (0.7)
Hematuria No bleeding event 150 (99.3) No bleeding event 143 (94.7)
One event 1 (0.7) One event 7 (4.6)
Two events 0 (0.0) Two events 1 (0.7)
Blood in stools No bleeding event 150 (99.3) No bleeding event 140 (92.7)
One event 1 (0.7) One event 11 (7.3)
Two events 0 (0.0) Two events 0 (0.0)
Nose bleed No bleeding event 150 (99.3) No bleeding event 149 (98.7)
One event 1 (0.7) One event 2 (1.3)
Two events 0 (0.0) Two events 0 (0.0)
Hemoptysis No bleeding event 150 (99.3) No bleeding event 147 (97.4)
One event 1 (0.7) One event 3 (2.0)
Two events 0 (0.0) Two events 1 (0.7)
Hematemesis No bleeding event 151 (100) No bleeding event 150 (99.3)
One event 0 (0.0) One event 1 (0.7)
Hematoma No bleeding event 150 (99.3) No bleeding event 149 (98.7)
One event 1 (0.7) One event 1 (0.7)
Two events 0 (0.0) Two events 1 (0.7)
Blood in phlegm or sputum No bleeding event 147 (97.4) No bleeding event 147 (97.4)
One event 4 (2.6) One event 4 (2.6)
Subconjunctival hemorrhage No bleeding event 150 (99.3) No bleeding event 148 (98.0)
One event 1 (0.7) One event 3 (2.0)
Two events 0 (0.0) Two events 0 (0.0)
Cerebrovascular accident (CVA) No bleeding event 151 (100) No bleeding event 149 (98.7)
One event 0 (0.0) One event 1 (0.7)
WMTAC protocol, an expanded INR reading within ±0.2 of
the actual reading can be accepted without any complications
(Table 5). Similar expanded range has been used in other studies
(Jo-Anne Wilson et al., 2003; Lalonde et al., 2008).
In this study, a few interventions were included during
consultation with patients during WMTAC, for example,
pharmacists’ recommendation in terms of dosage adjustment,
expanded therapeutic INR range, and missed doses for the
past week detected during WMTAC. Pharmacists also counsel
and monitor on drug–drug interactions, food interactions,
and consumption of traditional medicine or supplements.
Patients are educated with a list of green vegetables to
eat and a list of several common traditional medicines
or supplements. The results show the positive impact of
pharmacists’ recommendations in the WMTAC, as the number
of pharmacist recommendations accepted by the physician was
significantly increased in the WMTAC compared to the UMC
group. The pharmacists involved in WMTAC use the warfarin
protocol and have undergone training to learn about dosage
adjustment. Adjustment is done on the spot after the patients’
INR is detected. Hence this method also reduces patients’ waiting
time in the clinic.
Gupta et al. (2013) illustrated that the clinical pharmacists
exhibit their roles through assessment of patients’ adherence and
understanding of warfarin therapy, and frequent monitoring of
INR levels. Furthermore, pharmacists often detect and manage
adverse events or other medication-related problems. According
to the WMTAC protocol, all these details are necessary for
the purposes of counseling and charting progress. Pharmacists
will intervene and counsel toward increasing compliance and
adherence to warfarin therapy, as well as clinically significant
changes in diet (Gupta et al., 2013).
Findings of the study by Rossiter et al. (2013) showed that
in family medicine settings, pharmacist-led INR clinic improved
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control of anticoagulation therapy among AF patients on
warfarin therapy. There were similar findings in a study by Poon
et al. (2007) where the pharmacist-monitored anticoagulation
services were documented to lead to favorable outcomes in both
efficacy and warfarin-related complications. However, this study
only focused on patients over 75 years old.
After implementation of WMTAC protocol, greater emphasis
was given on pharmacists’ counseling on the compliance
issue, and to educate patients regarding missed doses and
time adjustment. Nevertheless, in current study, there was no
significant difference in missed doses among UMC and WMTAC
groups, as only one missed dose event was recorded throughout
the study.
Strengths and Limitations of the Study
This study adopted an observational methodology with a
retrospective cohort design. A retrospective design was deemed
appropriate as the data utilized in this study was already recorded
in a systematic way as part of patient care and the medical
staff were expected to routinely complete data documentation.
Generally, observational studies represent a valuable component
in investigation of treatment outcomes, and offer balanced
evidence base for clinical decision-making (Ligthelm et al.,
2007). Such detailed observations can be reliably replicated and
generalized to similar conditions or populations.
Retrospective data recalls exposures occurring sometime in
the past and are collected by searching medical records (Luepker,
2005). In addition, medical records are reliable data sources for
evaluation of existing conditions (Thomas et al., 2002).
Retrospective studies rely on medical staff documentation
rather than patient interviews. In the current study, all variables
needed to evaluate the objectives could be obtained from
medical staff and pharmacists’ documents, as well as information
sometimes obtained from the caregivers instead of the patients
themselves.
To minimize the potential for missing data, current study
measured confounding variable for all probable relevant
variables. All warfarin patients entered into the study were
followed up for the duration of the study. To avoid the effect of
data losses on validity of the results, missing data was minimized
by using prediction of regression statistics.
Moreover, retrospective data can be free from researcher
bias. In this study, all patients fulfilling the inclusion
criteria were screened, and researcher collected the relevant
data with no preconceived views of possible findings.
Furthermore, during review of the medical charts, a review
was conducted of the notes of cardiology consultants and
internal medical physicians, who are required to document
the full history, diagnosis, management, recommendations,
and preventive care strategies for all patients. Besides that,
usage of retrospective medical chart review is cheaper
and quicker to complete, while maintaining reliability of
information (Thomas et al., 2002). Data collection is reassessed
and reviewed by other researchers to reduce research
bias.
As this observational study was conducted in one hospital
only, the study has limitations in scope and generalizability.
Furthermore, due to limited sample size, the study did not involve
patients with other ailments (such as pulmonary embolism and
deep vein thrombosis) who were also attending warfarin clinic.
Randomization of patients was not considered, as this study
involved various modalities of treatment across the whole unit,
and a matched control unit was not available.
CONCLUSION
There is a significant positive association between the
pharmacist-led WMTAC and anticoagulation effect (therapeutic
TTR, INR). The identified findings show that expanded
role of pharmacist in PMWT is beneficial to optimize the
warfarin therapy. In such therapy, recommendations are made
such as dose adjustment, counseling on adherence and safer
alternative drugs (given drug–drug interactions and/or food–
drug interactions). This study also highlights the critical role that
pharmacists can actively play to ensure optimal anticoagulation
pharmaceutical care in collaboration with other healthcare teams.
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